2024
A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
Zhang J, Qu Z, Xiao X, Adelson D, Wang F, Wei A, Harata-Lee Y, Cui J, He D, Xie L, Sun L, Li J, Huang Z, Aung T, Yao H, Lin L. A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy. Heliyon 2024, 11: e41104. PMID: 39844968, PMCID: PMC11750466, DOI: 10.1016/j.heliyon.2024.e41104.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR-TKI-resistant cell linesNon-small cell lung cancerInhibition of drug resistanceLung cancerEpidermal growth factor receptor tyrosine kinase inhibitor resistanceDrug resistanceGrowth factor receptor tyrosine kinase inhibitorsCell linesReceptor tyrosine kinase inhibitorsEGFR-TKI resistanceResistance to gefitinibCell lung cancerFirst-line treatmentPI3K/AKT/mTOR pathwayMortality of lung cancerEGFR mutationsTreatment failureMolecular mechanismsDose-dependentlyKinase inhibitorsFlow cytometryAnticancer effectsGefitinibH1650 cells
2022
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm A, Tang J, Mills M, Liveringhouse C, Sandoval M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. Journal Of Neurosurgery 2022, 138: 1600-1607. PMID: 36681988, DOI: 10.3171/2022.9.jns221896.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesCancer brain metastasesSystemic therapyBrain metastasesStereotactic radiosurgeryCheckpoint inhibitorsLocal controlGrowth factor receptor tyrosine kinase inhibitorsSingle-fraction stereotactic radiosurgeryReceptor tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsKinase inhibitorsChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesTyrosine kinase inhibitorsBM diagnosisIntracranial controlBM patientsOverall survival
2021
Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e567. DOI: 10.1016/j.ijrobp.2021.07.1531.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesTiming of SRSChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesBrain metastasesCancer brain metastasesSystemic therapyRadiation necrosisStereotactic radiosurgeryCheckpoint inhibitorsOverall survivalTreatment groupsLocal controlMultivariate analysisBM patientsAlone groupClinical outcomesConventional chemotherapyGrowth factor receptor tyrosine kinase inhibitorsEfficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
Lee H, Jeong G, Li H, Kim M, Kim J, Park S, Han Y, Lee K, Kronbichler A, Hong S, Ghayda R, Luchini C, Nottegar A, Koyanagi A, Smith L, Jacob L, Dragioti E, Radua J, Cargnin S, Terrazzino S, Thompson T, Yon D, Lee S, Yang J, Wasuwanich P, Shin J, Gamerith G. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European Review For Medical And Pharmacological Sciences 2021, 25: 6232-6244. PMID: 34730203, DOI: 10.26355/eurrev_202110_26993.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR-mutant non-small cell lung cancerNon-small cell lung cancerProgression-free survivalSevere adverse eventsAdvanced EGFR-mutated non-small cell lung cancerSafety of epidermal growth factor receptor tyrosine kinase inhibitorsEpidermal growth factor receptor tyrosine kinase inhibitor therapyGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsStandard chemotherapyCell lung cancerOverall survivalAdverse eventsLung cancerKinase inhibitorsCompared to standard chemotherapyHazard ratioReducing severe adverse eventsAnalysis of adverse eventsIndirect meta-analysesChemotherapyCochrane LibraryInclusion criteriaSystemic review
2019
Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors
2018
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Wu YL, Herbst R, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer 2018, 19: e533-e536. PMID: 29789220, DOI: 10.1016/j.cllc.2018.04.004.Peer-Reviewed Original ResearchConceptsCell lung cancerDisease recurrenceLung cancerMutation statusSurvival rateEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsComplete surgical tumor resectionDisease-free survival ratesT790M mutation statusReceptor tyrosine kinase inhibitorsMaximum treatment durationStage IB-IIIAPlacebo-controlled studyDisease-free survivalEarly-stage NSCLCComplete surgical resectionOverall survival rateHealth-related qualityHealth resource useSurgical tumor resectionEGFR mutation statusTyrosine kinase inhibitorsCentral confirmationVersus Placebo
2017
Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications
Tsao C, Liaw B, He C, Galsky M, Sfakianos J, Oh W. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic Advances In Medical Oncology 2017, 9: 287-298. PMID: 28491148, PMCID: PMC5405995, DOI: 10.1177/1758834016687261.Peer-Reviewed Original ResearchRenal cell cancerCell cancerAnti-programmed cell death protein 1 immune checkpoint inhibitorVascular endothelial growth factor-targeted therapyEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTreatment of renal cell cancerReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsClinical trial testingCheckpoint inhibitorsKinase inhibitorsLethal malignancyTherapeutic implicationsDisease outcomeDisease biologyTherapyDrug developmentCancerDiseaseInhibitorsNivolumabMalignancyDrug
2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology 2015, 36: 5505-5513. PMID: 25669172, PMCID: PMC5573583, DOI: 10.1007/s13277-015-3218-4.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaReceptor tyrosine kinase inhibitorsHER2/neu gene amplificationTyrosine kinase inhibitorsUSC cell linesNeu gene amplificationEndometrial cancerIrreversible pan-ErbB receptor tyrosine kinase inhibitorEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsEpidermal growth factor receptor 2Cell linesKinase inhibitorsEffect of dacomitinibStandard salvage chemotherapyGrowth factor receptor 2Serous endometrial cancerFlow cytometry-based assayHER2/neuFactor receptor 2Dose-dependent declineGene amplificationCell cycle distributionCytometry-based assayGrowth inhibition
2014
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head & Neck 2014, 36: 1547-1554. PMID: 24123531, PMCID: PMC4010580, DOI: 10.1002/hed.23499.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCarcinoma, Squamous CellCell Line, TumorCell ProliferationDown-RegulationDrug Resistance, NeoplasmErlotinib HydrochlorideHead and Neck NeoplasmsHumansMiceMolecular Targeted TherapyMutationProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)QuinazolinesSensitivity and SpecificitySignal TransductionSquamous Cell Carcinoma of Head and NeckTransfectionConceptsShort hairpin RNACell linesHRAS expressionErlotinib sensitivityErlotinib-sensitive cell linesErlotinib-resistant cell linesErlotinib resistanceHras mutationsNeck squamous cell carcinoma cellsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinibNeck squamous cell carcinoma cell linesSquamous cell carcinoma cellsTyrosine kinase inhibitor erlotinibPanel of headReceptor tyrosine kinase inhibitorsHairpin RNAHNSCC cell linesSquamous cell carcinoma cell linesCell carcinoma cell linesCarcinoma cell linesKinase inhibitor erlotinibTyrosine kinase inhibitorsMutations
2013
Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist L, Ireland B, Stinchcombe TE. Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e341s-e368s. PMID: 23649446, PMCID: PMC4694611, DOI: 10.1378/chest.12-2361.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCetuximabErlotinib HydrochlorideGlutamatesGuanineHumansLung NeoplasmsNeoplasm StagingPatient SelectionPemetrexedPlatinum CompoundsProtein Kinase InhibitorsQuinazolinesConceptsStage IV non-small cell lung cancerNon-small cell lung cancerFirst-line therapyPerformance statusNonsquamous histologyLung cancerAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEastern Cooperative Oncology Group (ECOG) PSChest Physicians Lung Cancer GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsCell lung cancer diagnosisReceptor tyrosine kinase inhibitorsClinical patient characteristicsLung cancer guidelinesRole of cetuximabSafety of bevacizumabThird-line settingECOG performance statusGood performance statusPlatinum-based regimensPoor performance statusPhase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal Of Clinical Oncology 2013, 31: 1405-1414. PMID: 23460714, PMCID: PMC3612594, DOI: 10.1200/jco.2012.45.4272.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellDiarrheaDocetaxelDrug Administration ScheduleErbB ReceptorsFatigueFemaleGefitinibGenotypeHead and Neck NeoplasmsHumansKaplan-Meier EstimateLeukopeniaMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalProto-Oncogene ProteinsProto-Oncogene Proteins c-metProto-Oncogene Proteins p21(ras)Quinazolinesras ProteinsTaxoidsTreatment OutcomeConceptsAddition of gefitinibPerformance statusArm ADisease progressionEastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group trialEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsGrade 3/4 diarrheaPhase III randomizedSingle-agent gefitinibTrials of docetaxelUnplanned subset analysisECOG performance statusGrade 3/4 toxicitiesMedian overall survivalTime of progressionSquamous cell carcinomaTyrosine kinase inhibitorsEligible patientsMetastatic SCCHNWeekly docetaxelMetastatic headOverall survival
2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study
2010
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. Journal Of Clinical Oncology 2010, 28: 4747-4754. PMID: 20921467, PMCID: PMC3020704, DOI: 10.1200/jco.2009.27.9356.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCarcinoma, Non-Small-Cell LungCetuximabDisease-Free SurvivalDrug Administration ScheduleErbB ReceptorsErlotinib HydrochlorideFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingPaclitaxelPatient SelectionProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Quinazolinesras ProteinsResearch DesignSouthwestern United StatesTreatment OutcomeConceptsCell lung cancerConcurrent chemotherapyLung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsProgression-free survival timeRandomized phase II trialReceptor tyrosine kinase inhibitorsMedian overall survivalPaclitaxel/carboplatinTreatment-naive patientsGrade 3 rashPhase II trialAdvanced-stage NSCLCPhase III evaluationTyrosine kinase inhibitorsEnhanced antitumor activityConcurrent regimenMaintenance cetuximabMedian followVersus ChemotherapyChemotherapy regimenII trialSequential therapyConcurrent therapyDetection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabColorectal NeoplasmsErbB ReceptorsErlotinib HydrochlorideGefitinibHead and Neck NeoplasmsHumansKaplan-Meier EstimateLung NeoplasmsMass SpectrometryMutationProtein Kinase InhibitorsProteomicsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Quinazolinesras ProteinsSignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsCRC patientsColorectal cancerCancer patientsNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerRecurrent/metastatic headCell lung cancer patientsNeck squamous cell carcinomaLigand levelsReceptor tyrosine kinase inhibitorsCell lung cancerSquamous cell carcinomaLung cancer patientsKRAS mutation statusTyrosine kinase inhibitorsProteomic classificationSerum proteomic profilesDiverse cancer typesSite of originChemotherapy cohortMetastatic headPretreatment serumSurvival benefit
2009
A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG)
Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). Journal Of Clinical Oncology 2009, 27: 6011-6011. DOI: 10.1200/jco.2009.27.15_suppl.6011.Peer-Reviewed Original ResearchEastern Cooperative Oncology GroupMedian overall survivalArm AM SCCHNPrior chemotherapyAdverse eventsOverall survivalArm BCommon grade 3/4 adverse eventsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsECOG performance status 2Grade 3/4 adverse eventsGrade 5 adverse eventsMetastatic squamous cell carcinomaModest single-agent activityReceptor tyrosine kinase inhibitorsECOG PS 0Objective response ratePerformance status 2Phase III randomizedPlacebo-controlled trialTime of progressionCooperative Oncology GroupSingle-agent activity
2008
BATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination
Hong W, Herbst R, Mao L, Kim E. BATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination. 2008 DOI: 10.21236/ada485729.Peer-Reviewed Original ResearchNonsmall cell lung cancerLung cancerTargeted therapyAdvanced nonsmall cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsLung Cancer EliminationTumor response rateCell lung cancerLung cancer patientsCancer-related deathTyrosine kinase inhibitorsCancer patientsCancer eliminationEGFR mutationsTherapeutic approachesResponse rateCancerCancer typesPatientsKinase inhibitorsTherapyInitial successChemotherapy
2007
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2007, 25: 4743-4750. PMID: 17909199, DOI: 10.1200/jco.2007.12.3026.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Large CellCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDocetaxelErlotinib HydrochlorideFemaleGlutamatesGuanineHumansLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPemetrexedQuinazolinesSurvival RateTaxoidsTreatment OutcomeConceptsProgression-free survivalAdverse eventsLung cancerHumanized anti-vascular endothelial growth factor monoclonal antibodyRefractory non-small cell lung cancerAnti-vascular endothelial growth factor monoclonal antibodyEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerSingle-arm phase IRandomized phase II trialOne-year survival rateReceptor tyrosine kinase inhibitorsFatal pulmonary hemorrhagePlatinum-based regimenSafety of bevacizumabStudies of bevacizumabUnexpected safety signalsPhase II studySecond-line settingPhase II trialTreatment of recurrentCell lung cancerFactor monoclonal antibodyFavorable safety profileLessons learned in the development of targeted therapy for malignant gliomas
Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Molecular Cancer Therapeutics 2007, 6: 1909-1919. PMID: 17620423, DOI: 10.1158/1535-7163.mct-07-0047.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptorEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsPreliminary efficacy resultsPrognosis of patientsTranslational researchEndothelial growth factor receptorEffective treatment optionTyrosine kinase inhibitorsGrowth factor receptorRecurrent diseaseRapamycin inhibitorsPreclinical dataStandard treatmentTreatment optionsEfficacy resultsMalignant gliomasSuch tumorsNovel agentsAnaplastic astrocytomaMost trialsTrial designProtein kinase C betaPathway inhibitorA phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342
Herbst R, Chansky K, Kelly K, Atkins J, Davies A, Dakhil S, Albain K, Kim E, Crowley J, Gandara D. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. Journal Of Clinical Oncology 2007, 25: 7545-7545. DOI: 10.1200/jco.2007.25.18_suppl.7545.Peer-Reviewed Original ResearchNon-small cell lung cancerSmall-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorAdvanced non-small cell lung cancerAdvanced stage non-small cell lung cancerMetastatic non-small cell lung cancerStage non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsAdequate organ functionPhase III settingSuperior median survivalPhase II trialPhase III trialsCell lung cancerRandomized clinical trialsMolecular correlative studiesTyrosine kinase inhibitorsAnti-tumor activityPhase II selection trialTrue hazard ratioConcurrent chemotherapyConcurrent regimenEligible patientsEligible ptsKRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer. Clinical Cancer Research 2007, 13: 2890-2896. PMID: 17504988, DOI: 10.1158/1078-0432.ccr-06-3043.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideFemaleGefitinibGene DosageHumansLung NeoplasmsMaleMiddle AgedMutationPrognosisProtein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Quinazolinesras ProteinsTreatment OutcomeConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsCell lung cancerKRAS mutationsTyrosine kinase inhibitorsEGFR-TKIEGFR copy numberEGFR mutationsLung cancerFavorable responseKinase inhibitorsShorter median timeArchival tissue specimensEGFR gene mutationsPanel of markersAdvanced NSCLCObjective responseProgressive diseaseSurvival benefitMedian timePoor responseSuch therapyDisease progressionPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply